{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:40:57Z","timestamp":1767706857285,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"New Giza University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We intended to investigate the risk for second primary malignancy (SPM) development in Laryngeal Cancer (LC) survivors. We conducted a population-based analysis of SPM risk using the National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results (SEER) database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data of selected LC survivors from the SEER database between 2000 and 2020 were examined. Standardized Incidence ratios (SIRs) for SPM development were calculated, followed by detailed stratification according to anatomical site and different latency periods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 8413 SPMs were observed in our extracted cohort. The collective standardized incidence of SPMs was 2.12 (95% CI 2.07\u20132.17) compared to the US population, with an absolute excess risk (AER) of 201.73 per 10,000 individuals. The highest SPM risks were observed in patients with young age at diagnosis, females, and American Indians\/Alaska natives. Increased SPM risks were reported in patients receiving all modalities of treatment including surgery, chemotherapy, and radiotherapy. Most SPMs were detected in solid organs such as\u00a0the lungs and bronchus, oral cavity and pharynx, and prostate. The highest increased risks of developing SPMs were observed in Trachea, larynx, oral cavity and pharynx, lung and bronchus, and esophagus.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The risk of SPMs in LC survivors was significantly increased compared to the general US population. Accordingly, a more impactful cancer surveillance strategy for LC patients should be implemented.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00405-024-08731-9","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T14:02:12Z","timestamp":1716386532000},"page":"4409-4417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploring the risk of second primary malignancies in laryngeal cancer survivors: insights from the SEER database"],"prefix":"10.1007","volume":"281","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5007-5738","authenticated-orcid":false,"given":"Abdelrahman Yousry","family":"Afify","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-9309","authenticated-orcid":false,"given":"Mohamed Hady","family":"Ashry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"8731_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"8731_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"8731_CR3","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00405-016-4390-x","volume":"274","author":"J-J Zuo","year":"2017","unstructured":"Zuo J-J, Tao Z-Z, Chen C et al (2017) Characteristics of cigarette smoking without alcohol consumption and laryngeal cancer: overall and time-risk relation. A meta-analysis of observational studies. Eur Arch Otorhinolaryngol 274:1617\u20131631. https:\/\/doi.org\/10.1007\/s00405-016-4390-x","journal-title":"Eur Arch Otorhinolaryngol"},{"unstructured":"National Cancer Institute. SEER cancer statistics factsheets: laryngeal cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/laryn.html. Accessed 10 Mar 2024","key":"8731_CR4"},{"key":"8731_CR5","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00405-022-07730-y","volume":"280","author":"AY Afify","year":"2023","unstructured":"Afify AY, Ashry MH, Sadeq MA, Elsaid M (2023) Causes of death after laryngeal cancer diagnosis: a US population-based study. Eur Arch Otorhinolaryngol 280:1855\u20131864. https:\/\/doi.org\/10.1007\/s00405-022-07730-y","journal-title":"Eur Arch Otorhinolaryngol"},{"unstructured":"Surveillance, Epidemiology, and End Results (SEER) program (www.seer.cancer.gov) SEER*Stat database: incidence\u2014SEER research data, 17 registries, Nov 2022 Sub (2000\u20132020) for SMRs\u2014linked to county attributes\u2014total U.S., 1969\u20132021 counties","key":"8731_CR6"},{"unstructured":"Surveillance Research Program, National Cancer Institute. SEER*Stat software, version 8.4.3, released Jan 2024","key":"8731_CR7"},{"key":"8731_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/s0360-3016(02)04613-8","volume":"56","author":"X Gao","year":"2003","unstructured":"Gao X, Fisher SG, Mohideen N, Emami B (2003) Second primary cancers in patients with laryngeal cancer: a population-based study. Int J Radiat Oncol Biol Phys 56:427\u2013435. https:\/\/doi.org\/10.1016\/s0360-3016(02)04613-8","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"8731_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1200\/JCO.2010.31.8311","volume":"29","author":"LGT Morris","year":"2011","unstructured":"Morris LGT, Sikora AG, Patel SG et al (2011) Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 29:739\u2013746. https:\/\/doi.org\/10.1200\/JCO.2010.31.8311","journal-title":"J Clin Oncol"},{"key":"8731_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/ijc.IJC_273_18","volume":"56","author":"Y Ozdemir","year":"2019","unstructured":"Ozdemir Y, Topkan E (2019) Second primary malignancies in laryngeal carcinoma patients treated with definitive radiotherapy. Indian J Cancer 56:29. https:\/\/doi.org\/10.4103\/ijc.IJC_273_18","journal-title":"Indian J Cancer"},{"key":"8731_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/1097-0142(195309)6:5<963::aid-cncr2820060515>3.0.co;2-q","volume":"6","author":"DP Slaughter","year":"1953","unstructured":"Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6:963\u2013968. https:\/\/doi.org\/10.1002\/1097-0142(195309)6:5%3c963::aid-cncr2820060515%3e3.0.co;2-q","journal-title":"Cancer"},{"key":"8731_CR12","first-page":"4189","volume":"53","author":"M Nees","year":"1993","unstructured":"Nees M, Homann N, Discher H et al (1993) Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 53:4189\u20134196","journal-title":"Cancer Res"},{"key":"8731_CR13","first-page":"1676","volume":"53","author":"KY Chung","year":"1993","unstructured":"Chung KY, Mukhopadhyay T, Kim J et al (1993) Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 53:1676\u20131683","journal-title":"Cancer Res"},{"key":"8731_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/ijc.32101","volume":"145","author":"E Adjei Boakye","year":"2019","unstructured":"Adjei Boakye E, Buchanan P, Hinyard L et al (2019) Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States. Int J Cancer 145:143\u2013153. https:\/\/doi.org\/10.1002\/ijc.32101","journal-title":"Int J Cancer"},{"key":"8731_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","volume":"12","author":"AB de Gonzalez","year":"2011","unstructured":"de Gonzalez AB, Curtis RE, Kry SF et al (2011) Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 12:353\u2013360. https:\/\/doi.org\/10.1016\/S1470-2045(11)70061-4","journal-title":"Lancet Oncol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08731-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-024-08731-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08731-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T19:47:27Z","timestamp":1721764047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-024-08731-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["8731"],"URL":"https:\/\/doi.org\/10.1007\/s00405-024-08731-9","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"type":"print","value":"0937-4477"},{"type":"electronic","value":"1434-4726"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"30 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable (non-human participant research).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}